Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07081532 in Type 2 Diabetes and Obesity
NCT04305587Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lotiglipron in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Treatment-Related Adverse Events, Number of Participants With Laboratory Abnormalities and 2 more. Started Mar 2020; status: completed.
02
Drugs
lotiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04305587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305587.